Be Alert to Stocks with the Greatest % Change in Volume

Be Alert to Stocks with the Greatest % Change in Volume

All newspapers show the 15 most active stocks, usually consisting of securities like IBM, AT&T, or General Motors, which each normally trade more than a million shares a day. Investor's Business Daily, on the other hand, shows a table of the "Common Stocks with the Greatest % Rise in Volume." This spotlights companies that have the largest increase above their own last 50 days of average daily trading volume.

The list is valuable because the computer surveillance picks up the small- and medium-sized, innovative, entrepreneurial organizations that may have a 500% increase in trading volume but never reach a total volume figure large enough to make the more commonly followed "Most
Active" lists. These sophisticated screens may not appear in other publications. Pay close attention to the boldfaced stocks on the list.

Some newspapers list the stocks that are up most, percentagewise, in price. This list is almost universally worthless because it will show a $2 stock up /s of a point as stock up in price the greatest percent. They also show preferred stocks in the list. Low-priced stocks and preferred
issues are of little use to most informed investors. You can't get rich prospecting in the junk pile.

Eliminating the cheaper, less relevant, low-quality stocks, plus the preferred issues, and concentrating on a meaningful list of 25 of the more significant securities or higher is more useful. Stocks in this list that have options listed show a small "o" after the company's name
to assist option traders.

Most newspapers typically provide a small block, "How to Read the Daily Stock Tables." Be absolutely sure to read these instructions as you would directions to any new product you buy. You'll learn many helpful facts that will save you money.

Tags: stock market, stocks, stock market useful guide, stocks tips, Earn Money from stock, How to make money in stock market

stocks: Pipavav Shipyard

Pipavav Shipyard
BSE:533107
CMP:57.60
Volume: 1376372

Our sources suggest that one of the leading broking fIrms has been accumulating Pipavav Shipyard in a big way. The firm is bullish on the counter and our sources hint at some fireworks before X’Mas on the counter. The scrip is available at Rs 58. Go for it to add to the cheerfulness of the season.

Free Marketing And Advertising Information - POAD Blog

Stocks: SAIL

SAIL
BSE :500113
CMP:188
Volume: 1838799
This PSU steel company saw some renewed interest on the bourses as some of the domestic as well as foreign funds are looking at it from an investment point of view. They feel that the counter will command a good premium due to better liquidity on account of its planned FPO. The counter is available at Rs 190 and is expected to provide capital appreciation of near about 10 per cent in one month’s time with target price of Rs 210.

Stocks: Mahindra Satyam

Mahindra Satyam
BSE: 500376
CMP: 103.4
Volume: 8712057
One of the market veterans has been very bullish on this counter and he believes that it will emerge as one of the best out-performers in the IT pack. The counter has been down by 12 per cent in the last one week and is available at Rs 104. The target for the scrip has been put at Rs 140 by Diwali next year. Would you like to follow him?

Stocks: Reliance Capital

Reliance Capital
BSE: 500111
NSE: 908.25
Volume: 3036810
After the Mukesh Ambanicontrolled Reliance Industries declared a bonus, now our sources suggest that Reliance Capital, controlled by Anil Ambani, may soon announce one too. Our sources further claim that the counter will surge in the corning days as this bonus will be well- appreciated by the inves • tars. However, a point to be noted is that the • Reliance Industries’ bonus announcement did not really enthuse the investots to the level expected and so one cannot be sure of what response Reliance Capital will fetch from them. But do expect some wild movement on either side. If you wish play on the counter go for a straddle strategy on F&O.

Stocks: Ratnamani Metals

Ratnamani Metals
BSE:520H1
CMP: 102.25
Volume: 126968
One of the domestic research houses that also has forayed into mutual funds, has been tracking this Ahmedabad-based pipe company and has come out with a ‘buy’ report as it feels that the scrip is likely to be a winner on the bourses due to a huge latent demand for power projects. The scrip is available at Rs 102 and is expected to provide capital appreciation in the region of 30-40 per cent in one year’s time.

Stocks: Buy SAIL

 

SAIL bottomed out by posting an intra-week low of Rs. 091.50 during the week ended 09th March 2007, staged a smart rally but ran into resistance from the 116 level during the week ended 30th March 2007. The scrip couldn’t sustain these levels for long, but recovered smartly, and peaked by posting an intra-week high of Rs. 167.10 during the week ended 20th July 2007. SAIL declined from here, struggled a bit, entered a medium term uptrend, appreciated to peak at an intra-week high of Rs. 292.50 during the week ended 14th December 2007. The scrip declined rather sharply from here, received support from the 055 level to bottom out by posting an intra-week low of Rs. 055.25 during the week ended 21st November 2008 only to stage a smart recovery. Currently Sail Limited is
in the process of commencing its medium term uptrend after a corrective movement on the weekly chart and with the mechanical indicators looking positive, a further upside from these levels cannot be ruled out.

Stochastic-Buy ROC-Buy RSI-Buy Resistance: 196, 210 55 Week EMA: 167.03
Trading Pointers:
Indicators : MACIl-Sell RMI-SeU
Support: 173, 155
BSE Code —500113

Stocks: Buy Financial Tech

Financial Tech, bottomed out by posting an intra-week low of Rs. 988.05 during the week ended 16th June 2006, took support on the 999 level, commenced a short term uptrend, rallied to peak at an intraweek high of Rs. 2225.00 during the week ended 01st December 2006. The scrip couldn’t sustain these levels for long, almost took support on the 1641 level to actually bottom out by posting an intra-week low of Rs. 1641.35 during the week ended 09th March 2007. Financial Tech. moved sideways for the next few weeks — recovered to peak at an intraweek high of Rs. 3048.00 during the week ended 29th June 2007 only to decline from here. Currently the scrip seems to be on the verge of forming a higher top, higher bottom formation on the daily chart due to significant support at lower levels, could commence a medium term uptrend and with the weekly mechanical indicators also looking better, indicating the possibility of a further upside from these levels.

Trading Pointers:
Indicators: MACD-Sel RMI-SeII Stochastic-Buy ROIl-Buy RSI-Buy
Support: 1366, 1257 Resistance:1467, 1519
BSE Code —526881 55 Week EMA:121 2.57

Stocks: Buy GSK Pharma |

GSK Pharma peaked at an intra-week high of Rs. 1148.95 during the week ended 11th January 2008, entered a corrective phase, struggled a bit but couldn’t manage to overcome the 1149 level, declined to post an intra-week low of Rs. 800.00 during the week ended 25th January 2008. The scrip staged a smart recovery from here, peaked at an intra-week high of P.s. 1205.00 during the week ended 29th February 2008 only to enter a corrective phase. GSK Pharma couldn’t sustain these levels for long, declined to post an intra-week low of Rs. 930.00 during the week ended 31st October 2008. The scrip staged a superb recovery from here and rallied to peak at an intra-week high of P.s. 1619.65 during the week ended 01st October 2009 and entered a cortective phase. Currently GSK Pharma has reversed direction after receiving significant support from the 1500 level and with the mechanical indicators supporting the move; a weekly close above the 1671 level would mean the possibility of a frirther upside from here.

Trading Pointers:
Indicators : MACIl-Buy RM[Buy Stochastic-Buy ROIl-Buy RSI-Buy
Support: 1638, 1558 Resistance:1700, 1800
BSE Code —500660 55 Week EMA: 1328.77

stocks:Bajaj Hind

Bajaj Hind, bottomed out by posting an intra-week low of Rs. 115.55 during the week ended 24th August 2007. The scrip launched into an intermediate uptrerid, posted a series of progressively higher tops and bottoms and rallied to peak at an intra-week high of Rs. 199.00 during the week ended 28th September 2007. Bajaj Hind, couldn’t sustain these levels for long, declined to post an intra-week low of Rs. 144.25 during the week ended 12th October 2007. The scrip commenced its uptrend, from here, rallied after almost receiving support from the 55 Week EMA, started moving within the confines of an upward sloping channel, rallied to peak at an intra-week high of Rs. 399.50 during the week ended 11th January 2008 only to enter a deep corrective phase. The scrip rallied to peak at an intra-week high of Rs. 241.80 during the week ended 23rd October 2009. Currently Bajaj Hind, seems set to stage a upmove after what can only be described as a weekly correction, the mechanical indicators are supporting the move and with even the weekly picture looking better, a further upside from these levels cannot be ruled out.

Trading Pointers:
ndicators : MACD-Buy RMI-Buy Stochastic-Buy ROC-Buy RSI-Buy
Support: 222, 195 Resistance : 242, 262
BSE Code -500032 55 Week EMA: 157.90

Low Priced Stocks : Natural Capsules (NCL)

with the valuations of the front-runners getting steeper day by day, it makes sense to look out for fundamentally strong scrips that are still available at low valuations. Keeping this thought in mind, we at DSIJ have short-listed Natural Capsules for our recommendation in this column. There are certain companies which maintain a low profile and continue to grow almost unnoticed over the years. Thus, despite their performances these scrips fail to catch the investors’ fancy, when they actually could be a good pick for the portfolio. Almost an unheard name, Natural Capsules (NCL) is a similar story.

Based out of Bangalore, the company is basically into the manufacturing and marketing of gelatin capsule shells, which contributes 91 per cent to its total revenues, while the balance 9 per cent comes from contract manufacturing. The management, however, claims that contract manufacturing isn’t a major focus area for the company. NCL’s manufacturing facilities are based in Bangalore and Puducherry and it boasts of clientele such as Cipla, Aurobindo Pharma, Flamingo Pharmaceuticals, Kopran, Milan Labs etc. These top five clients contribute 35-40 per cent to its total revenues.

Primarily, what makes NCL attractive is its consistent performance. NCL has been growing at a five-year CAGR of over 20 per cent in the topline and 15 per cent the bottomline. Despite a tough last fiscal wherein companies across the board saw their revenues and profits shrinking; NCL has managed not only to grow in both topline and profits, but also has expanded its operating margins by 107 basis points. In fact, it has continued with this performance in the first half of this fiscal and has seen a further margin expansion of 104 basis points.

However, NCL wants to grow more briskly and has undertaken a capacity expansion plan wherein it would see its manufacturing capability grow by more than double to 7.35 billion capsules by June 2010 from its current limit of 3.62 billion capsules. The total cost of this expansion is about Rs 15 crore and is being funded a combination of debt and equity. NCL has already imported three capsule manufacturing machines, one of which is already commissioned, while the other two would be fully operational by June 2010. Once this happens it will push NCLs revenues to another trajectory altogether. The management is targeting revenues Rs 45 crore by FY11. That apart, NCL has also been paying dividend since the five years. In FY09 its dividend of 12 per cent worked out a dividend yield of almost 3 per cent. This limits any downside risk for the scrip. NCL has continued with its good work and managed to put up a decent performance in the first half as well wherein its topline increased by 10 per cent to Rs 14.17 crore (Rs 12.89 crore), while the bottomlirie increased by 43.42 per cent to Rs 2.51 crore (Rs 1.75 crore) account of better cost management.

For FY10 we expect NCL could post revenues of Rs 29 crore, while profits could around Rs 5.07 crore. At these estimates, NCL gives an EPS of Rs 11.26, thereby resulting in an estimated PE of just 3.7x. This is certainly worth a grab. In fact, on EVIEBDITA basis as well the scrip is available at 3x, which is quite attractive. Besides, at its two-week average quantity of 23,526, the volumes are quite healthy the scrip. Hence, it makes sense to buy Natural Capsules at its CMP of Rs 42.75, with a one year target price of Rs 55.

IPCA stock seems a compelling growth story

 Tags: IPCA , IPCA LABORATORIES, IPCA stocks,

IPCA LABORATORIES Rs894 PE14.4

With high earnings visibility, a diversified portfolio and resilient growth, the IPCA stock seems a compelling growth story

aying a reasonable price for a stock is important, more so in an expensive market.  hese days, many companies look promising, but most of theirs stock prices have, possibly, run ahead of their intrinsic value. IPCA Laboratories a mid-sized pharmaceutical manufacturer where that has not happened despite the visibility on future earnings.

The company’s main business is manufacturing drug formulations. It started  manufacturing active pharmaceutical ingredients (API) and intermediaries to strengthen its drug formulations activity. Today, IPCA is a vertically integrated pharma company with API, intermediaries and formulations in its product portfolio, and has presence in more than hundred countries.

Business performance. The formulations business is IPCAs major revenue earner, contributing about 72 per cent to net sales at the end of FY09. API and intermediarjes formed the remaining 28 per cent. The company has focussed equally on both these segments, which has resulted in their healthy growth. During FY09, the company’s formulations business grew 18 per cent over the last year, and sales of API and intermediaries grew 31 per cent. IPCA has a diversified product portfolio covering therapeutic groups. It includes cardiovascular and anti-diabetic drugs, non-steroidal anti-inflammatory drugs, and anti-bacterial and anti-malarial drugs. The cardiovascular and anti-diabetic segment contributes the most to the company’s formulation revenues. These are lifestyle-related drugs that have immense potential in a country like India. With focus on the Indian market, the company is now expanding its portfolio with new launches in the lifestyle-related segment.

IPCA is also geographically diversified. In FY09, over 50 per cent of its revenue came from exports to regions such as Europe, the Americas and Africa. Despite the global downturn in FY09, the company’s exports grew by an impressive 27 per cent compared to around 5 per cent growth for the global pharmaceutical market.

Financial performance. IPCA has announced impressive results for the quarter ending September 2009 (Q2FY1O). Net total income moved up 24 per cent on a year-on-year (y-o-y) basis. The operating margin remained flat over Q2FYO9. The growth in profit was high at 75 per cent, although it was on last year’s low base (last year’s profits were affected by forex losses). The strong performance in the last quarter is not entirely a one-off. IPCA has been growing at a healthy pace for a long time. The compounded growth rate for its total income over the last 10 years is close to 14 per cent, with income from domestic sales and exports growing at almost the same pace. IPCA has also changed its product mix by shifting its dependence from low margin anti-malarial drugs to high-margin chronic and lifestyle medicines. The strategy has helped it grow its margins.

Valuation. IPCAs share price has doubled in value over the last year. Despite this, it is trading 14 times its trailing 12 months’ earnings per share. This value is attractive compared to the industry’s price-earnings multiple of 30. Also, the company is growing faster than both the domestic and the global pharma industry. Its last quarter growth figure is among the highest in the sector.

In future, exports will be the major driver of the company’s growth. In developed markets, it is building presence in generic medicines while in emerging markets, it is focused more on branded products. The company’s growing product portfolio in the lifestyle segment will also help it maintain strong growth in the domestic market. All this makes IPCA an investor’s pick in an expensive market. ii

Stocks: Zee News (ZNL)

1&64%
LTP: Rs 52.50
M Cap: Rs 1,259cr

Zee News (ZNL) has seen delivery volumes rise 137 per cent with 1,651,205 shares changing hands. The company recently announced a share swap ratio of 4:19 for the transfer of its regional general entertainment channels to Zee Entertainment Enterprises (ZEEL). So, for every 19 shares of ZNL held, four shares of ZEEL will be issued. Also, ZEEL will also assume debt of Rs 120 crore from total net debt of Rs 150 crore on Zee News’ books. According to Vikash Mantri of ICICI Securities, the news business’ profitability is expected to improve in the current fiscal on the back of lower losses from new initiatives due to conversion of the Tamil GEC, Zee Tamizh, into a predominantly news channel. For the September quarter, revenues grew 26.3 per cent y-o-y to Rs 161.2 crore on the back of a 26.4 per cent y-o-y and a 17.3 per cent q-o-q growth in advertising revenues. I-Sec has a ‘Buy’ rating on the stock with a target price of Rs 60, based on Rs 50 a share for the regional channels business (as per the announced swap ratio) and Rs 10 a share for the residual news business based on FYi 1 E EV/ sales of lx.

Stocks: Tata Motors

7.68%
LTP: Rs 569.95
M Cap: Rs 30,111 cr

The country’s biggest commercial vehicle manufacturer, which holds close to 65 per cent share of the market, saw delivery volumes rise 88 per cent with close to 1,561,523 shares changing hands. The company has seen one of the best monthly sales in recent time in October, with sales growing 35 per cent to 53,404 units. Passenger vehicle sales in the domestic market grew by 17.61 per cent to 20,011 units last month. The company doubled its quarterly profit to Rs 729 crore owing to softer raw material costs and a revival in vehicle sales. According to Sahil Kedia of Enam Securities, the recovery in CV sales is expected to continue in the second half of the fiscal. However, Ebitda margins will be under pressure owing to higher commodity costs.

Stocks: Suzlon

2131% Down
LTP: Rs 66.30
M Cap: Rs 10,321 cr

Beleaguered wind power supplier Suzlon saw delivery volumes jump 74 percent following news that the company had managed to get fresh dollar loans to refinance its $465 million debt payable this month. According to market sources, Axis Bank and State Bank of India will finance this loan, which will be payable at Libor-plus 550 bps within the next five years after an initial two-year moratorium. Following this transaction, Suzion will have raised its stake in Repower to 100 per cent from its present level of
91 per cent. Also in the news was that Indiabulls Financial had hiked its stake in the company to 6.38 per cent from earlier levels of 4.59 per cent following the acquisition of pledged shares. As of September 09, promoters have pledged 43.28 per cent of their stake, amounting to 23.98 per cent of total outstanding. The company still has a net debt of Rs 12,525 crore. Even after the stock having lost 21 per cent last fortnight, the outlook still remains weak.

Stocks: Shriram Transport

Tags: shriram Transport, Sriram, Stock Market, Stock Signs, Stock Watch

1.65% Down
LTP: Rs 390.40
M Cap: Rs 8262 Cr

The stock of the country’s largest commercial vehicle financier dipped a little under 2 per cent during the fortnight with a 150 per cent surge in delivery volumes. The stock was In the centre of action on November 4 as private equity firm Chrys Capital sold its 2.13 per cent stake for Rs 1743 crore. The PE firm had sold a partial stake in the NBFC last year. The Chennai’based Shriram group company saw its profit after tax rise 25,26 per cent in the September quarter to Rs 207,45-core. Revenues grew by 1741 percent to Rs 1,071.61 -crore. Total assets under martagei-nent at the end of the quarter stood at Rs 25,823.75-crore. Read More 

 According to Kotak Institutional Equities, the NBFC will deliver 24 per cent CAGR in core profit before tax (excluding provisions) between FY09 and FYi 1 and generate medium-term return on equity of about 26-29 per cent.

Stocks: Punji Lloyd

Tags: Stocks,  Punji Lloyd, Stock Market, Stock Signs,
18.48% Down
LIP:Rs 212.15
M Cap: 7.039 Cr

The country’s second’largest infrastructure major, primarily catering to the oil and gas space, was down 18.5 per cent during the fortnight ended November 6, At Rs 212.15, the stock is down 29 per cent from its 52-week high levels of Rs 299 clocked just a month ago, The company is facing challenges in the operations of its UK-based wholly owned subsidiary, Simon Carves, in terms of cost overruns and delays in the Completion of bioethanol project, which also affected its profitability In the first half of the current fiscal, Read More

Stocks: Punjab National Bank

 Tags: Stocks: Punjab National Bank, Punjab, National Bank, Stock Market, Stock Signs, Stock Watch
2.70% Up
LIP: Is 88170
M Cap: Is 28,071 Cr

The stock oldie country’s Second-largest public sector lender rose by nearly 3per cent over the fortnight with 95 per cent spurt in delivery volumes, The bank has been the talk of the town owing to Its renewed focus on International banking, post the irwjuctiori of the new chairman and managing director, KR Kamath,
Read More
who was the earlier heading Aliahabad Bank. In order to expand its presence In central Asia, the state owned lender will ac.quire a majority stake in Dana Bank based in Kazakhstan, The bank has also received RBI approval for setting up a subsidiary at Vancouver and to upgrade their representative office at Shanghai to a branch. PNB posted a net profit of Rs 926 crore in the September quarter compared with Rs 7O7crore In the corresponding quarter in the previous year Motilal Oswal has a ‘buy’ rating on the stock with a target of Rs 1,053, “We are Impressed by the sharp decline in the cost of deposits, improved yields in the quarter and traction on CASA growth. While 6 per cent restructured loan5 are relatively higher compared with BoB, Canara Bank and Union Bank. we believe our FY10 and Fyi 1 credit costs assumptions capture the likely asset quality deterioration,” states the report.
;1]

Stocks: JK Lakshmi Cement

Tags: JK Lakshmi Cement, Stocks, Stock Market, Stock Signs

2.90% UP
LTP:Rs125.40
MCap:Rs767a

Although cement may be going out of favour on concerns of a supply glut setting in next year onwards, JK Lakshmi Cement seems incredibly cheap and this could trigger some value buying in the stock. Read More

Stocks: Crompton Greaves

10.90% Up
[TP Ri 384.15
M(ap: Rs 14,082cr

The stock price of the power equipment major gained 11 per cent on the back of heavy volumes during the fortnight ended November 6, thanks to the robust 02 results announced on October 27. The company reported the highest growth In operating profit and net profit, since the past four quarters, at 43 per cent and 47 per cent, respectively. The top line grew a strong 16 per cent to Rs 1,268.60 crore. Though the stock looks a bit stretched at 18 times estimated FY11 earnings, it is worth watching the company as It has reported stable performance even in the tough quarters of December 2008 and March 2009.